Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride

BJU International

Volumn 99, Issue 3, 2007, Pages 587-594

  Hahn, Robert G ^a   Fagerström, Tim ^a   Tammela, Teuvo L J ^b   Van Vierssen Trip, Oncko ^c   Beisland, Hans Olav ^d   Duggan, Annette ^e   Morrill, Betsy ^f  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c GELDERSE VALLEI HOSPITAL   (Netherlands)

^d Sorlandet Hospital   (Norway)

^e GLAXOSMITHKLINE   (United Kingdom)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Blood loss; Blood vessels; BPH; Double blind; Dutasteride; Mannitol; Surgical; TURP

Indexed keywords

ACETYLSALICYLIC ACID; ANDROSTANOLONE; ANTICOAGULANT AGENT; DUTASTERIDE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MICROVASCULATURE; MULTICENTER STUDY; PHOTOMETER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRANSURETHRAL RESECTION; TREATMENT DURATION; URINE INCONTINENCE;

AGED; AGED, 80 AND OVER; AZASTEROIDS; BLOOD LOSS, SURGICAL; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROSTATIC HYPERPLASIA; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME;

EID: 33846934500     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06619.x     Document Type: Article

References (30)

1. Uchida T, Ohori M, Soh S et al. Factors influencing morbidity in patients undergoing transurethral resection of the prostate. Urology 1999; 53: 98-105
2. Ekengren J, Hahn RG. Blood loss during transurethral resection of the prostate as measured with the HemoCue photometer. Scand J Urol Nephrol 1993; 27: 501-7
3. Carlin BI, Bodner DR, Spirnak JP, Resnick MI. Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate 1997; 31: 180-2
4. Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 1998; 51: 237-40
5. Sieber PR, Rommel FM, Huffnagle HW et al. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. J Urol 1998; 159: 1232-3
6. Foley SJ, Soloman LZ, Wedderburn AW et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 2000; 163: 496-8
7. Delakas D, Lianos E, Karyotis I, Cranidis A. Finasteride: a long-term follow-up in the treatment of recurrent hematuria associated with benign prostatic hyperplasia. Urol Int 2001; 67: 69-72
8. Foley SJ, Bailey DM. Microvessel density in prostatic hyperplasia. BJU Int 2000; 85: 70-3
9. Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000; 55: 684-9
10. Ukimura O, Kawauchi A, Kanazawa M et al. Preoperative administration of chlormadinone acetate reduces blood loss associated with transurethral resection of the prostate: a prospective randomized study. BJU Int 2005; 96: 98-102
11. Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002; 168: 2024-6
12. Crea G, Sanfilippo G, Anastasi G, Magno C, Vizzini C, Inferrera A. Presurgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int 2005; 74: 51-3
13. Özdal ÖL, Özden C, Benli K, Gokkaya S, Bulut S, Memis A. Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate Cancer Prostatic Dis 2005; 8: 215-8
14. Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 2001; 58: 972-6
15. Lund L, Möller Ernst-Jensen K, Torring N, Erik Nielsen J. Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. Scand J Urol Nephrol 2005; 39: 160-2
16. Boccon-Gibod L, Valton M, Ibrahim H, Boccon-Gibod L, Comenducci A. [Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate]. Prog Urol 2005; 15: 1085-9
17. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 1997; 282: 1496-502
18. Roehrborn CG, Andriole G, Schalken JA, Wilson T, Clark RV. Dutasteride, a novel dual 5-alpha reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients. Eur Urol Suppl 2003; 2: 161, Abstract 635
19. Wurzel R, Ray P, Major-Walker K, Shannon J. Inhibition of type I and type II 5-alpha reductase with dutasteride (0.5 mg) significantly reduces intraprostatic dihydrotestosterone in BPH patients. AUA Meeting 2006 (Abstract)
20. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol 1995; 154: 1779-82
21. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243-7
22. Hahn RG. Influence of variations in blood haemoglobin concentration on the calculation of blood loss and volumetric irrigating fluid balance during transurethral resection of the prostate. Br J Anaesth 1987; 59: 1223-9
23. Jansen H, Berseus O, Johansson JE. A simple photometric method for determination of blood loss during transurethral surgery. Scand J Urol Nephrol 1978; 12: 1-5
24. Marshall S, Narayan P. Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation. J Urol 1993; 149: 1553-4
25. Lekas E, Bergh A, Damber JE. Effects of finasteride and bicalutamide on prostatic blood flow in the rat. BJU Int 2000; 85: 962-5
26. Andriole G, Humphrey P, Ray P et al. Effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol 2004; 172: 915-9
27. Haggstrom S, Torring N, Moller K et al. Effects of finasteride on vascular endothelial growth factor. Scand J Urol Nephrol 2002; 36: 182-7
28. Canda AE, Mungan MU, Yilmaz O, Yorukoglu K, Tuzel E, Kirkali Z. Effects of finasteride on vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. Int Urol Nephrol 2006; 38: 275-80
29. Pareek G, Shevchuk M, Armenakas NA et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol 2003; 169: 20-3
30. Donohue JF, Hayne D, Karnik U, Thomas DR, Foster MC. Randomized, placebocontrolled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int 2005; 96: 1319-22